A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
Clinical trial NCT03445533 · TERMINATED
Trial details
- NCT number
- NCT03445533
- Sponsor
- Idera Pharmaceuticals, Inc.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-05-30
- Primary completion
- 2021-06-01
- Enrollment
- 481
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.